Clinicians’ attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Naomi Bradbury, Jonathan Nguyen-Van-Tam, Wei Shen Lim

ABSTRACT

BACKGROUND: The value of neuraminidase inhibitors (NAIs) in reducing severe clinical outcomes from influenza is debated. A clinical trial to generate better evidence is desirable. However, it is unknown whether UK clinicians would support a placebo-controlled trial. A survey was conducted to determine the attitude of clinicians towards a clinical trial and their current practice in managing adults admitted to hospital with suspected influenza. METHODS: Senior clinicians (n = 50) across the UK actively involved in the care of patients hospitalised with severe respiratory infections and/or respiratory infection research were invited to participate in an on-line survey. Participants were asked their opinion on the evidence for benefit of NAIs in influenza, their current practice in relation to: a) testing for influenza; b) treating empirically with NAIs; and c) when influenza infection is virolologically confirmed, prescribing NAIs. RESULTS: Thirty-five (70%) of 50 clinicians completed the survey. Respondents were drawn mainly from infectious diseases, intensive care and respiratory medicine. Only 11 (31%) of 35 respondents agreed that NAIs are effective at reducing influenza mortality; 14 (40%) disagreed, 10 (28.6%) neither agreed nor disagreed. When managing adults admitted to non-ICU wards with a respiratory infection during an influenza season, 15 (51.7%) clinicians indicated they would usually perform a test for influenza in greater than 60% of patients but only 9 (31%) would treat empirically with NAIs in greater than 60% of patients. Few clinicians would either test or empirically treat patients presenting with other (non-respiratory infection related) diagnoses. If influenza infection is confirmed, 17 (64.5%) clinicians would prescribe NAIs in greater than 80% of patients with a respiratory infection treated on non-ICU wards Thirty-one (89%) clinicians agreed that a placebo-controlled clinical trial should be conducted and 29 (85%) would participate in such a trial. CONCLUSIONS: There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults hospitalised with suspected influenza. Current variation in medical opinion and clinical practice demonstrates collective equipoise, supporting ethical justification for a trial. Low use of NAIs in the UK suggests randomisation of treatment would not substantially divert patients towards placebo. More... »

PAGES

311

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x

DOI

http://dx.doi.org/10.1186/s12913-018-3122-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103738626

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29716584


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Attitude of Health Personnel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoside Hydrolase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitalization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Influenza, Human", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medical Staff, Hospital", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuraminidase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oseltamivir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Personnel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Zanamivir", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Warwick", 
          "id": "https://www.grid.ac/institutes/grid.7372.1", 
          "name": [
            "Zeeman Institute: Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, CV4 7AL, Coventry, UK", 
            "School of Life Sciences, University of Warwick, CV4 7AL, Coventry, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bradbury", 
        "givenName": "Naomi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Faculty of Medicine & Health Sciences, University of Nottingham. Clinical Sciences Building, Nottingham City Hospital, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nguyen-Van-Tam", 
        "givenName": "Jonathan", 
        "id": "sg:person.01317574115.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317574115.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, City Hospital Campus, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lim", 
        "givenName": "Wei Shen", 
        "id": "sg:person.012720025352.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012720025352.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1136/bmj.g2545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004439783"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)61734-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007587958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.04623-14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014888384"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)62449-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018993023"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/15265161.2015.1010993", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025900421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0001296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030246057"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2213-2600(14)70041-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030941184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jinf.2013.11.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031506364"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198707163170304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043033182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3201/eid2206.151037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049764978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(15)70106-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052987598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0079360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053423666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0079360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053423666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thoraxjnl-2011-200081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053544632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thoraxjnl-2011-200081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053544632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/medethics-2016-103474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062819666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/medethics-2016-103474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062819666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2807/1560-7917.es2015.20.11.21065", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070926445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta19160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2807/1560-7917.es.2017.22.14.30506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084954433"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.j2841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085998696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.j2841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085998696"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: The value of neuraminidase inhibitors (NAIs) in reducing severe clinical outcomes from influenza is debated. A clinical trial to generate better evidence is desirable. However, it is unknown whether UK clinicians would support a placebo-controlled trial. A survey was conducted to determine the attitude of clinicians towards a clinical trial and their current practice in managing adults admitted to hospital with suspected influenza.\nMETHODS: Senior clinicians (n\u00a0=\u200950) across the UK actively involved in the care of patients hospitalised with severe respiratory infections and/or respiratory infection research were invited to participate in an on-line survey. Participants were asked their opinion on the evidence for benefit of NAIs in influenza, their current practice in relation to: a) testing for influenza; b) treating empirically with NAIs; and c) when influenza infection is virolologically confirmed, prescribing NAIs.\nRESULTS: Thirty-five (70%) of 50 clinicians completed the survey. Respondents were drawn mainly from infectious diseases, intensive care and respiratory medicine. Only 11 (31%) of 35 respondents agreed that NAIs are effective at reducing influenza mortality; 14 (40%) disagreed, 10 (28.6%) neither agreed nor disagreed. When managing adults admitted to non-ICU wards with a respiratory infection during an influenza season, 15 (51.7%) clinicians indicated they would usually perform a test for influenza in greater than 60% of patients but only 9 (31%) would treat empirically with NAIs in greater than 60% of patients. Few clinicians would either test or empirically treat patients presenting with other (non-respiratory infection related) diagnoses. If influenza infection is confirmed, 17 (64.5%) clinicians would prescribe NAIs in greater than 80% of patients with a respiratory infection treated on non-ICU wards Thirty-one (89%) clinicians agreed that a placebo-controlled clinical trial should be conducted and 29 (85%) would participate in such a trial.\nCONCLUSIONS: There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults hospitalised with suspected influenza. Current variation in medical opinion and clinical practice demonstrates collective equipoise, supporting ethical justification for a trial. Low use of NAIs in the UK suggests randomisation of treatment would not substantially divert patients towards placebo.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12913-018-3122-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1327417", 
        "issn": [
          "1472-6963"
        ], 
        "name": "BMC Health Services Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "name": "Clinicians\u2019 attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza", 
    "pagination": "311", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2a3c22a2da426e8cd5ed219da38866756423496f8b9bda848e218d5d54a42410"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29716584"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101088677"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12913-018-3122-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103738626"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12913-018-3122-x", 
      "https://app.dimensions.ai/details/publication/pub.1103738626"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89801_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12913-018-3122-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12913-018-3122-x'


 

This table displays all metadata directly associated to this object as RDF triples.

200 TRIPLES      21 PREDICATES      62 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12913-018-3122-x schema:about N092354224bc74d0aa6aa555b5b966792
2 N1be5b3bfdbfe4efab838071f48dcc240
3 N30549d0e5d2a44bdaec59b2159daf75d
4 N3cca9bf22ae24083b9480cfd3d96401c
5 N4dba9f0d5cf745089502b06cf5dde5e3
6 N51d85840490f439aa3dc673419578337
7 N725f76982b1543b99a49f6500a7f1122
8 N9533f0c59f3546509a2b14ccd2f670ed
9 N9d61e65b0d1f446ebb2f0eee0a39ed92
10 Naf18ca36d99d4c5c9dd80fd99e9ebf3f
11 Nb607b6aee1de48b580fd7c50836b4f56
12 Nd5f329935dea4111b5cd932cdb0c0b5e
13 Ne94709f28b1c4b50b71d9a18af4029a0
14 Neeeb6148e0a64312aa29348cc09c3330
15 Nf2a5d7eacea94f0c8b4ce9858277158b
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N449cb28f79924d7d89bb92d0127ced49
19 schema:citation https://doi.org/10.1016/j.jinf.2013.11.013
20 https://doi.org/10.1016/s0140-6736(14)61734-7
21 https://doi.org/10.1016/s0140-6736(14)62449-1
22 https://doi.org/10.1016/s1473-3099(15)70106-4
23 https://doi.org/10.1016/s2213-2600(14)70041-4
24 https://doi.org/10.1056/nejm198707163170304
25 https://doi.org/10.1080/15265161.2015.1010993
26 https://doi.org/10.1128/aac.04623-14
27 https://doi.org/10.1136/bmj.g2545
28 https://doi.org/10.1136/bmj.j2841
29 https://doi.org/10.1136/medethics-2016-103474
30 https://doi.org/10.1136/thoraxjnl-2011-200081
31 https://doi.org/10.1371/journal.pone.0001296
32 https://doi.org/10.1371/journal.pone.0079360
33 https://doi.org/10.2807/1560-7917.es.2017.22.14.30506
34 https://doi.org/10.2807/1560-7917.es2015.20.11.21065
35 https://doi.org/10.3201/eid2206.151037
36 https://doi.org/10.3310/hta19160
37 schema:datePublished 2018-12
38 schema:datePublishedReg 2018-12-01
39 schema:description BACKGROUND: The value of neuraminidase inhibitors (NAIs) in reducing severe clinical outcomes from influenza is debated. A clinical trial to generate better evidence is desirable. However, it is unknown whether UK clinicians would support a placebo-controlled trial. A survey was conducted to determine the attitude of clinicians towards a clinical trial and their current practice in managing adults admitted to hospital with suspected influenza. METHODS: Senior clinicians (n = 50) across the UK actively involved in the care of patients hospitalised with severe respiratory infections and/or respiratory infection research were invited to participate in an on-line survey. Participants were asked their opinion on the evidence for benefit of NAIs in influenza, their current practice in relation to: a) testing for influenza; b) treating empirically with NAIs; and c) when influenza infection is virolologically confirmed, prescribing NAIs. RESULTS: Thirty-five (70%) of 50 clinicians completed the survey. Respondents were drawn mainly from infectious diseases, intensive care and respiratory medicine. Only 11 (31%) of 35 respondents agreed that NAIs are effective at reducing influenza mortality; 14 (40%) disagreed, 10 (28.6%) neither agreed nor disagreed. When managing adults admitted to non-ICU wards with a respiratory infection during an influenza season, 15 (51.7%) clinicians indicated they would usually perform a test for influenza in greater than 60% of patients but only 9 (31%) would treat empirically with NAIs in greater than 60% of patients. Few clinicians would either test or empirically treat patients presenting with other (non-respiratory infection related) diagnoses. If influenza infection is confirmed, 17 (64.5%) clinicians would prescribe NAIs in greater than 80% of patients with a respiratory infection treated on non-ICU wards Thirty-one (89%) clinicians agreed that a placebo-controlled clinical trial should be conducted and 29 (85%) would participate in such a trial. CONCLUSIONS: There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults hospitalised with suspected influenza. Current variation in medical opinion and clinical practice demonstrates collective equipoise, supporting ethical justification for a trial. Low use of NAIs in the UK suggests randomisation of treatment would not substantially divert patients towards placebo.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree true
43 schema:isPartOf N56fdcfb9214a4ef59df3f74907e5f5c3
44 N66e3bb16e10b4735b41682848cd98027
45 sg:journal.1327417
46 schema:name Clinicians’ attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza
47 schema:pagination 311
48 schema:productId N2d3697b2445d45198ac8c1ec66d11bf6
49 N97e0d2a564cc4e96904257e9b7ed725f
50 N9eecd9cd0fdb484cb7a047db9f94acb1
51 Nad8a9115dce94810b03103dad7bec6b5
52 Ne214906294fc429591f8327378ad353e
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103738626
54 https://doi.org/10.1186/s12913-018-3122-x
55 schema:sdDatePublished 2019-04-11T09:55
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher Ndea8730a277b4140a61286ea62e21cda
58 schema:url https://link.springer.com/10.1186%2Fs12913-018-3122-x
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N092354224bc74d0aa6aa555b5b966792 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Humans
64 rdf:type schema:DefinedTerm
65 N1be5b3bfdbfe4efab838071f48dcc240 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Glycoside Hydrolase Inhibitors
67 rdf:type schema:DefinedTerm
68 N2d3697b2445d45198ac8c1ec66d11bf6 schema:name dimensions_id
69 schema:value pub.1103738626
70 rdf:type schema:PropertyValue
71 N30549d0e5d2a44bdaec59b2159daf75d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Research Personnel
73 rdf:type schema:DefinedTerm
74 N3803a14aeaf7439fa4297ae3f772ae44 rdf:first sg:person.01317574115.29
75 rdf:rest N95ec0c6465c9432b89c4263ed5fca635
76 N3cca9bf22ae24083b9480cfd3d96401c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Neuraminidase
78 rdf:type schema:DefinedTerm
79 N449cb28f79924d7d89bb92d0127ced49 rdf:first N981aa99d30af4a3a816ffd4f7d254693
80 rdf:rest N3803a14aeaf7439fa4297ae3f772ae44
81 N4dba9f0d5cf745089502b06cf5dde5e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Oseltamivir
83 rdf:type schema:DefinedTerm
84 N51d85840490f439aa3dc673419578337 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Zanamivir
86 rdf:type schema:DefinedTerm
87 N56fdcfb9214a4ef59df3f74907e5f5c3 schema:volumeNumber 18
88 rdf:type schema:PublicationVolume
89 N66e3bb16e10b4735b41682848cd98027 schema:issueNumber 1
90 rdf:type schema:PublicationIssue
91 N725f76982b1543b99a49f6500a7f1122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Attitude of Health Personnel
93 rdf:type schema:DefinedTerm
94 N9533f0c59f3546509a2b14ccd2f670ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Randomized Controlled Trials as Topic
96 rdf:type schema:DefinedTerm
97 N95ec0c6465c9432b89c4263ed5fca635 rdf:first sg:person.012720025352.64
98 rdf:rest rdf:nil
99 N97e0d2a564cc4e96904257e9b7ed725f schema:name readcube_id
100 schema:value 2a3c22a2da426e8cd5ed219da38866756423496f8b9bda848e218d5d54a42410
101 rdf:type schema:PropertyValue
102 N981aa99d30af4a3a816ffd4f7d254693 schema:affiliation https://www.grid.ac/institutes/grid.7372.1
103 schema:familyName Bradbury
104 schema:givenName Naomi
105 rdf:type schema:Person
106 N9d61e65b0d1f446ebb2f0eee0a39ed92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Surveys and Questionnaires
108 rdf:type schema:DefinedTerm
109 N9eecd9cd0fdb484cb7a047db9f94acb1 schema:name doi
110 schema:value 10.1186/s12913-018-3122-x
111 rdf:type schema:PropertyValue
112 Nad8a9115dce94810b03103dad7bec6b5 schema:name nlm_unique_id
113 schema:value 101088677
114 rdf:type schema:PropertyValue
115 Naf18ca36d99d4c5c9dd80fd99e9ebf3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Adult
117 rdf:type schema:DefinedTerm
118 Nb607b6aee1de48b580fd7c50836b4f56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Antiviral Agents
120 rdf:type schema:DefinedTerm
121 Nd5f329935dea4111b5cd932cdb0c0b5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Medical Staff, Hospital
123 rdf:type schema:DefinedTerm
124 Ndea8730a277b4140a61286ea62e21cda schema:name Springer Nature - SN SciGraph project
125 rdf:type schema:Organization
126 Ne214906294fc429591f8327378ad353e schema:name pubmed_id
127 schema:value 29716584
128 rdf:type schema:PropertyValue
129 Ne94709f28b1c4b50b71d9a18af4029a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Influenza, Human
131 rdf:type schema:DefinedTerm
132 Neeeb6148e0a64312aa29348cc09c3330 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Hospitalization
134 rdf:type schema:DefinedTerm
135 Nf2a5d7eacea94f0c8b4ce9858277158b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name United Kingdom
137 rdf:type schema:DefinedTerm
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
142 schema:name Clinical Sciences
143 rdf:type schema:DefinedTerm
144 sg:journal.1327417 schema:issn 1472-6963
145 schema:name BMC Health Services Research
146 rdf:type schema:Periodical
147 sg:person.012720025352.64 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
148 schema:familyName Lim
149 schema:givenName Wei Shen
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012720025352.64
151 rdf:type schema:Person
152 sg:person.01317574115.29 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
153 schema:familyName Nguyen-Van-Tam
154 schema:givenName Jonathan
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317574115.29
156 rdf:type schema:Person
157 https://doi.org/10.1016/j.jinf.2013.11.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031506364
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/s0140-6736(14)61734-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007587958
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/s0140-6736(14)62449-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018993023
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1016/s1473-3099(15)70106-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052987598
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1016/s2213-2600(14)70041-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030941184
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1056/nejm198707163170304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043033182
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1080/15265161.2015.1010993 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025900421
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1128/aac.04623-14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014888384
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1136/bmj.g2545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004439783
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1136/bmj.j2841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085998696
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1136/medethics-2016-103474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062819666
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1136/thoraxjnl-2011-200081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053544632
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1371/journal.pone.0001296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030246057
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1371/journal.pone.0079360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053423666
184 rdf:type schema:CreativeWork
185 https://doi.org/10.2807/1560-7917.es.2017.22.14.30506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084954433
186 rdf:type schema:CreativeWork
187 https://doi.org/10.2807/1560-7917.es2015.20.11.21065 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070926445
188 rdf:type schema:CreativeWork
189 https://doi.org/10.3201/eid2206.151037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049764978
190 rdf:type schema:CreativeWork
191 https://doi.org/10.3310/hta19160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139472
192 rdf:type schema:CreativeWork
193 https://www.grid.ac/institutes/grid.412920.c schema:alternateName Nottingham City Hospital
194 schema:name Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, City Hospital Campus, NG5 1PB, Nottingham, UK
195 Faculty of Medicine & Health Sciences, University of Nottingham. Clinical Sciences Building, Nottingham City Hospital, NG5 1PB, Nottingham, UK
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.7372.1 schema:alternateName University of Warwick
198 schema:name School of Life Sciences, University of Warwick, CV4 7AL, Coventry, UK
199 Zeeman Institute: Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, CV4 7AL, Coventry, UK
200 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...